Intellia Therapeutics Inc Stock News

Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

These biotech stocks have missed out on market gains so far, falling in the double digits over the past year. But they are innovators with potential growth catalysts right around the corner.

Cathie Wood added to her positions in these biotech stocks this week. The famous investor seeks out undervalued innovators to add to her funds and hold onto for the long term.

When it comes to risk vs. reward in the stock market, the biotech sector has one of the highest potential payoffs.

Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.

Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.

Intellia Therapeutics has two candidates in or close to entering late-stage studies. The company's shares could rise significantly if it records positive trial results.

Intellia Therapeutics is expected to give updates on a pair of programs. The quality of its data will determine how much the market reacts.

While the stock market is not yet free of recessionary fears and remains affected by high interest rates, 2024 has, so far, brought significant positive developments if things are to be judged by majo

Intellia Therapeutics, Inc. (NTLA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NTLA broke through the 50-day moving average, whi

Ark Invest bought shares of Roku, 10x Genomics, and Intellia Therapeutics on Monday. Roku has shed more than one-third of its value over the past two weeks after a series of unfortunate events.

Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, NTLA crossed above the 20-day moving avera

Intellia's (NTLA) earnings beat estimates in the fourth quarter while the company reports negative revenues. Management provides developmental and regulatory updates on its key pipeline candidates.

The consensus price target hints at an 185.5% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.